An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Revvity, Inc. (NYSE: RVTY) unveils the Auto-Pure 2400 liquid handler for use with the T-SPOT.TB test, revolutionizing tuberculosis testing. The new system substantially reduces hands-on time, boosting lab productivity. Labs, clinicians, and patients benefit from the efficient workflow and clinical accuracy of the combined solution.
Revvity, Inc. (NYSE: RVTY) presenta il manipolatore di liquidi Auto-Pure 2400 per l'uso con il test T-SPOT.TB, rivoluzionando il test per la tubercolosi. Il nuovo sistema riduce notevolmente il tempo di manipolazione diretta, aumentando la produttività del laboratorio. Laboratori, clinici e pazienti traggono vantaggio dal flusso di lavoro efficiente e dalla precisione clinica della soluzione combinata.
Revvity, Inc. (NYSE: RVTY) revela el manejo de líquidos Auto-Pure 2400 para utilizar con el test T-SPOT.TB, revolucionando las pruebas de tuberculosis. El nuevo sistema reduce sustancialmente el tiempo de manipulación directa, mejorando la productividad del laboratorio. Los laboratorios, clínicos y pacientes se benefician del flujo de trabajo eficiente y de la precisión clínica de la solución combinada.
Revvity, Inc. (NYSE: RVTY)는 T-SPOT.TB 검사에 사용되는 Auto-Pure 2400 액체 핸들러를 공개하여 결핵 검사를 혁신합니다. 새로운 시스템은 직접적인 조작 시간을 크게 줄여 실험실 생산성을 향상시킵니다. 실험실, 의료진 및 환자는 효율적인 워크플로우와 결합된 솔루션의 임상 정확성으로 혜택을 받습니다.
Revvity, Inc. (NYSE: RVTY) dévoile le manipulateur de liquides Auto-Pure 2400 pour l'utilisation avec le test T-SPOT.TB, révolutionnant ainsi les tests de la tuberculose. Le nouveau système réduit considérablement le temps de manipulation directe, améliorant ainsi la productivité du laboratoire. Les laboratoires, cliniciens et patients bénéficient du flux de travail efficace et de la précision clinique de la solution combinée.
Revvity, Inc. (NYSE: RVTY) enthüllt den Auto-Pure 2400 Flüssigkeitshandler für den Einsatz mit dem T-SPOT.TB-Test und revolutioniert damit die Tuberkulose-Tests. Das neue System reduziert erheblich die direkte Handhabungszeit und steigert die Produktivität im Labor. Labore, Kliniker und Patienten profitieren von dem effizienten Arbeitsablauf und der klinischen Genauigkeit der kombinierten Lösung.
Positive
None.
Negative
None.
The integration of the Auto-Pure 2400 with the T-SPOT.TB test in Revvity's product line is a notable advancement in the field of laboratory diagnostics. The T-SPOT.TB is a proven test for identifying latent tuberculosis and its pairing with an automated liquid handling platform can significantly enhance lab efficiency. This can potentially lead to increased throughput and reduced operational costs for laboratories, which is a compelling value proposition. However, from an investment perspective, it is essential to observe the market adoption rate of this new system. One must consider the capital expenditures labs may face when upgrading and the potential impact on Revvity’s revenue streams. Long-term success will depend on clinical acceptance and the scalability of production to meet demand.
Revvity's move to automate tuberculosis testing is in alignment with the broader trend of automation in healthcare diagnostics. As demand for quick and reliable diagnostic tests grows, innovations such as these are critical for staying competitive in the industry. The key metrics to evaluate would be the improvement in turnaround time for tests and the reduction in human error rates. Furthermore, the ability of the platform to handle mid-to-high volume settings could open up new market segments for Revvity, possibly driving revenue growth. Still, one must weigh the costs associated with the implementation and training required against the anticipated gains in productivity and accuracy.
New and improved workflow now available that pairs Revvity’s T-SPOT™.TB test with the Auto-Pure 2400 liquid handling platform
Substantially lowers hands-on time, allowing for increased lab productivity
WALTHAM, Mass.--(BUSINESS WIRE)--
Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution.
“The ability to use the Auto-Pure 2400 platform with our T-SPOT.TB test provides labs an efficient workflow allowing latent TB testing to be run in a mid-high-volume setting, without having to compromise on the clinical performance of the test,” said Darren Sher, general manager, infectious diseases for Revvity. “With this solution, more labs can offer clinicians access to the most accurate TB diagnostic on the market.”
Auto-Pure 2400 liquid handler for use with the T-SPOT.TB test
The Auto-Pure 2400 automated liquid handling platform is equipped with integrated magnetic cell isolation technology.
Designed for testing up to 24 samples per run, it completes day-1 T-SPOT.TB workflows in under 3.5 hours, requiring only a single mid-run user interaction.
The solution not only simplifies lab workflows but also boasts an intuitive software user interface.
The T-SPOT.TB test detects latent tuberculosis infection (LTBI) and is an interferon-gamma release assay (IGRA) based on the enzyme-linked immunospot (ELISPOT) technology.
This technology has crucial steps that the World Health Organization has recently recognized as critical in ensuring reliable and accurate TB test results. These steps include washing, isolating, and counting peripheral blood mononuclear cells (PBMCs) before conducting the test.
Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
What did Revvity announce regarding tuberculosis testing?
Revvity, Inc. (NYSE: RVTY) launched the Auto-Pure 2400 liquid handling platform for use with the T-SPOT.TB test.
How does the Auto-Pure 2400 system improve lab productivity?
The Auto-Pure 2400 system substantially lowers hands-on time, allowing for increased lab productivity.
What benefits do labs, clinicians, and patients gain from the new solution?
The combined solution of the T-SPOT.TB test with the Auto-Pure 2400 system provides an efficient workflow and clinical accuracy, benefiting labs, clinicians, and patients.
How many samples can the Auto-Pure 2400 handle per run?
The Auto-Pure 2400 can handle up to 24 samples per run, completing day-1 T-SPOT.TB workflows in under 3.5 hours.
What technology is integrated into the Auto-Pure 2400 liquid handler?
The Auto-Pure 2400 is equipped with integrated magnetic cell isolation technology.
Who is the general manager of infectious diseases at Revvity?
Darren Sher is the general manager of infectious diseases for Revvity.
What is the primary focus of the Auto-Pure 2400 liquid handler?
The primary focus of the Auto-Pure 2400 liquid handler is to streamline lab workflows and provide an efficient solution for tuberculosis testing.
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.
